

Ermanno Puxeddu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5022611/publications.pdf>

Version: 2024-02-01

58
papers

1,275
citations

393982

19
h-index

377514

34
g-index

58
all docs

58
docs citations

58
times ranked

1792
citing authors

#	ARTICLE	IF	CITATIONS
1	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 11-16.	2.0	159
2	Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , 2017, 124, 6-14.	1.3	131
3	Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , 2016, 17, 70.	1.4	71
4	Adherence to COPD treatment: Myth and reality. <i>Respiratory Medicine</i> , 2017, 129, 117-123.	1.3	64
5	The prevalence of asthma and COPD in Italy: A practice-based study. <i>Respiratory Medicine</i> , 2011, 105, 386-391.	1.3	55
6	Searching for the synergistic effect between acclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , 2015, 109, 1305-1311.	1.3	54
7	Airflow obstruction: is it asthma or is it COPD?. <i>International Journal of COPD</i> , 2016, Volume 11, 3007-3013.	0.9	52
8	LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. <i>European Respiratory Review</i> , 2017, 26, 160043.	3.0	50
9	Iron laden macrophages in idiopathic pulmonary fibrosis: The telltale of occult alveolar hemorrhage?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 28, 35-40.	1.1	49
10	Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation. <i>PLoS ONE</i> , 2018, 13, e0194803.	1.1	49
11	Interaction between corticosteroids and muscarinic antagonists in human airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 36, 1-9.	1.1	47
12	Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. <i>Respiratory Research</i> , 2019, 20, 104.	1.4	45
13	Are there pulmonary sequelae in patients recovering from COVID-19?. <i>Respiratory Research</i> , 2020, 21, 286.	1.4	42
14	HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2015, 45, 483-490.	3.1	33
15	Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101841.	1.1	32
16	Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014, 31, 191-7.	0.2	31
17	Interaction of brefeldin A-inhibited guanine nucleotide-exchange protein (BIG) 1 and kinesin motor protein KIF21A. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 18788-18793.	3.3	29
18	Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD. <i>Current Opinion in Pharmacology</i> , 2018, 40, 39-45.	1.7	29

#	ARTICLE	IF	CITATIONS
19	Interaction of phosphodiesterase 3A with brefeldin A-inhibited guanine nucleotide-exchange proteins BIG1 and BIG2 and effect on ARF1 activity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6158-6163.	3.3	23
20	A potential role of triple therapy for asthma patients. Expert Review of Respiratory Medicine, 2019, 13, 1079-1085.	1.0	18
21	An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. International Journal of Mycobacteriology, 2016, 5, 244-247.	0.3	15
22	Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Molecular Diagnosis and Therapy, 2019, 23, 603-614.	1.6	15
23	An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. Expert Review of Respiratory Medicine, 2018, 12, 43-54.	1.0	14
24	Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 50, 28-37.	1.1	13
25	A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. Respiratory Medicine, 2013, 107, 2014-2021.	1.3	12
26	Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine. EBioMedicine, 2017, 19, 14-15.	2.7	12
27	Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. European Respiratory Journal, 2017, 49, 1602345.	3.1	11
28	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. Journal of Affective Disorders, 2021, 278, 339-340.	2.0	11
29	Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respiratory Medicine, 2013, 107, 107-111.	1.3	10
30	Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert Opinion on Pharmacotherapy, 2021, 22, 611-620.	0.9	10
31	Reactivity to Mycobacterial Antigens by Patients with Löfgren's Syndrome as a Model of Phenotypic Susceptibility to Disease and Disease Progression. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 685-685.	2.5	8
32	Acute COPD exacerbation: 3T MRI evaluation of pulmonary regional perfusion " Preliminary experience. Respiratory Medicine, 2014, 108, 875-882.	1.3	8
33	The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. BioMed Research International, 2016, 2016, 1-7.	0.9	8
34	Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2016, 39, 48-53.	1.1	7
35	DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE.. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019065.	0.5	7
36	Dual bronchodilation and exacerbations of COPD. Journal of Thoracic Disease, 2016, 8, 2383-2386.	0.6	6

#	ARTICLE	IF	CITATIONS
37	A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety, 2018, 17, 509-517.	1.0	6
38	The prognostic role of Genderâ€­Ageâ€­Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. Clinical Respiratory Journal, 2019, 13, 166-173.	0.6	6
39	Synergy across the drugs approved for the treatment of asthma. Minerva Medica, 2022, 113, .	0.3	6
40	Structured multidisciplinary discussion of HRCT scans for IPF/UIP diagnosis may result in indefinite outcomes. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32, 32-6.	0.2	6
41	Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. Respiratory Medicine, 2021, 189, 106639.	1.3	4
42	Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Immunology: in Practice, 2017, 5, 873.	2.0	3
43	Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. Monaldi Archives for Chest Disease, 2021, , .	0.3	3
44	Olodaterol + tiotropium bromide for the treatment of COPD. Expert Review of Respiratory Medicine, 2016, 10, 379-386.	1.0	2
45	Indacaterol/Glycopyrronium Combination for COPD. Pulmonary Therapy, 2017, 3, 45-57.	1.1	2
46	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulmonary Pharmacology and Therapeutics, 2018, 49, 20-26.	1.1	2
47	Biomarkers for possible early detection and progression of idiopathic pulmonary fibrosis. Minerva Respiratory Medicine, 2021, 60, .	0.1	2
48	Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 403-405.	0.6	1
49	Protein tyrosin kinase and KCa++ channel: two faces of the same coin in LABA/LAMA synergy. , 2017, , .		1
50	Clinical synergism of LABA/LAMA combinations in COPD patients. , 2017, , .		1
51	CD71â„ Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1444-1446.	2.5	0
52	A six minute walking test (6MWT) derived index (O2-GAP) predicts mortality in IPF. , 2015, , .		0
53	Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate. , 2016, , .		0
54	The trend of pulmonary function tests over time in COPD patients with different levels of blood eosinophils. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
55	Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone. , 2016, , .		0
56	Cytofluorimetric BAL cells characterization in IPF and in other ILD. , 2016, , .		0
57	Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations. , 2018, , .		0
58	Prevalence and clinical relevance of comorbidities in IPF. , 2018, , .		0